Day: August 12, 2022

Renewable Gasoline Company Bluescape Clean Fuels, LLC to Become Publicly Traded on NASDAQ via Business Combination with CENAQ Energy Corp. and be renamed Verde Clean Fuels, LLC

Renewable Gasoline Company Bluescape Clean Fuels, LLC to Become Publicly Traded on NASDAQ via Business Combination with CENAQ Energy Corp. and be renamed Verde Clean Fuels, LLC

Bluescape Clean Fuels, LLC is positioned to be a leading supplier of gasoline derived from renewable feedstocks through the development of multiple facilities across the United States The transaction is expected to provide the combined company with a minimum of $80 million in gross proceeds from a simultaneous PIPE financing with proceeds to be utilized towards construction of Verde Clean Fuels’ first commercial production facility After CENAQ shareholder approval and closing of the transaction, the combined company is expected to have a pro forma enterprise value of $280 million and a pro forma implied market capitalization of $500 million assuming no redemptions by CENAQ shareholders HOUSTON, Aug. 12, 2022 (GLOBE NEWSWIRE) — CENAQ Energy Corp. (NASDAQ: CENQ) (“CENAQ”), a special purpose acquisition company focused on energy...

Continue reading

IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Unveiled a new preclinical program focused on developing iPSC derived gamma-delta T cells and presented early findings at the ASGCT Annual Meeting. Presented data from Phase 1 clinical trial of INB-200 in patients with newly diagnosed GBM showing five of six fully dosed patients exceeded both median and expected progression free survival (PFS), with a sixth patient early in follow up; two patients have exceeded overall survival (OS) benchmarks established by Stupp et al, 2005 to-date. Continued to demonstrate durable morphologic complete responses from INB-100 Phase 1 clinical trial in leukemia patients with two of three patients relapse free at two years to date and all three relapse free past one year. Appointed seasoned executives to the roles of Senior Vice President, Business Development, Vice President, Regulatory Affairs, and Vice...

Continue reading

Apollo Tactical Income Fund Inc. Declares August 2022 Monthly Distribution of $0.097 Per Share

Apollo Tactical Income Fund Inc. Declares August 2022 Monthly Distribution of $0.097 Per Share

NEW YORK, Aug. 12, 2022 (GLOBE NEWSWIRE) — (NYSE: AIF) – Apollo Tactical Income Fund Inc. (the “Fund”) today announced the declaration of its distribution for the month of August 2022 of $0.097 per common share, payable on the date noted below. The following dates apply to the declared distribution: Ex-Date: August 22, 2022Record Date: August 23, 2022Payment Date: August 31, 2022Per Share Amount: $0.097 Apollo Contact Information: Product Literature877-864-4834 InvestorsElizabeth BesenInvestor Relations ManagerApollo Global Management, Inc.212-822-0625ebesen@apollo.com Forward-Looking Statements This press release may contain statements that are forward looking, as that term is defined by the Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission in its rules, regulations and releases....

Continue reading

Apollo Senior Floating Rate Fund Inc. Declares August 2022 Monthly Distribution of $0.092 Per Share

Apollo Senior Floating Rate Fund Inc. Declares August 2022 Monthly Distribution of $0.092 Per Share

NEW YORK, Aug. 12, 2022 (GLOBE NEWSWIRE) — (NYSE: AFT) – Apollo Senior Floating Rate Fund Inc. (the “Fund”) today announced the declaration of its distribution for the month of August 2022 of $0.092 per common share, payable on the date noted below. The following dates apply to the declared distribution: Ex-Date: August 22, 2022Record Date: August 23, 2022Payment Date: August 31, 2022Per Share Amount: $0.092 Apollo Contact Information: Product Literature877-864-4834 InvestorsElizabeth BesenInvestor Relations ManagerApollo Global Management, Inc.212-822-0625ebesen@apollo.com Forward-Looking StatementsThis press release may contain statements that are forward looking, as that term is defined by the Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission in its rules, regulations and releases....

Continue reading

Hour Loop Reports Second Quarter 2022 Results

Hour Loop Reports Second Quarter 2022 Results

Demonstrates Strong Execution Despite Challenging Macroeconomic Environment and Unfavorable e-Commerce Traffic in Q2 Provides Full Year 2022 Revenue Guidance Range of $81 million to $90 million REDMOND, Wash., Aug. 12, 2022 (GLOBE NEWSWIRE) — Hour Loop, Inc. (NASDAQ: HOUR) (“Hour Loop”), a leading online retailer, announces its financial and operational results for the second quarter ended June 30, 2022. Financial Highlights for Second Quarter 2022: Total revenues increased 27.1% and 19.8% to $14.8 million, compared to $11.6 million in the year-ago period and $12.4 million for the first quarter of 2022, respectively. Net loss totaled $0.31 million, compared to net income of $1.1 million in the year-ago period and net loss of $0.65 million for the first quarter of 2022. Cash used in operating activities for the six months ended...

Continue reading

Beam Global Reports Fiscal Q2 2022 Financial Results

Beam Global Reports Fiscal Q2 2022 Financial Results

Conference Call Friday August 12, 2022 at 4:30 p.m. ET SAN DIEGO, Aug. 12, 2022 (GLOBE NEWSWIRE) — Beam Global, (Nasdaq: BEEM, BEEMW), (the “Company”), the leading provider of innovative sustainable products and technologies for electric vehicle (EV) charging, energy storage, energy security and outdoor media, today announced the financial results for the second fiscal quarter ended June 30, 2022. Fiscal Q2 2022 and Recent Company Highlights Generated the highest second quarter revenue in the company’s history of $3.7 million, a 75% increase over Q2 2021 Generated highest first half revenue in the company’s history of 7.5M, a 114% increase over first half 2021 Improved Gross Profitability in first half by 4% of revenue despite inflation Reduced net loss by over 14% of revenue in first half despite inflation and acquisition Grew...

Continue reading

Nova LifeStyle, Inc. Reports Second Quarter FY 2022 Results

Nova LifeStyle, Inc. Reports Second Quarter FY 2022 Results

LOS ANGELES, Aug. 12, 2022 (GLOBE NEWSWIRE) — Nova LifeStyle, Inc. (NASDAQ: NVFY) (“Nova LifeStyle” or the “Company”) today announced its financial results for the second quarter ended June 30, 2022. Key Financial Highlights: Operating Results for the Three Months Ended June 30, 2022 Net sales for three months ended June 30, 2022 were $3.8 million, an increase of 7% from $3.5 million in the same period of 2021. Gross loss was ($3.5 million), compared to ($4 million) in the same period of 2021. Net loss was ($5.7 million), compared to ($6.3 million) loss in the same period of 2021. Operating Results for the Six Months Ended June 30, 2022 Net sales for the six months ended June 30, 2022 were $7.5 million, an increase of 9% from $6.9 million in the same period 2021. Gross (loss) was ($2.0 million), compared to ($2.6 million) in...

Continue reading

Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business Updates

Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business Updates

– Positive Data from the Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia (ET) Presented at European Hematology Association (EHA) Meeting 2022 – – Positive Data from the Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis Presented at EHA 2022 – – First Participant Dosed in Investigator-Sponsored Phase 1/2 Study of Bomedemstat in Combination with Atezolizumab in Small Cell Lung Cancer – – Obtained Advice from FDA Clinical Outcomes Assessment (COA) Group with Regard to Patient Reported Outcome (PRO) Endpoints for the Company’s Planned Phase 3 Trial of Bomedemstat in ET Patients – SOUTH SAN FRANCISCO, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) — Imago BioSciences, Inc. (“Imago” or the “Company”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering...

Continue reading

Jasper Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

Jasper Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

First patient dosed in a sponsored trial of JSP191 conditioning in patients with Fanconi Anemia On schedule to initiate a registrational study in AML in the first quarter of 2023 On schedule to initiate a new study of JSP191 as a therapeutic in second-line therapy for lower-risk, transplant ineligible MDS patients later this year REDWOOD CITY, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on developing multiple new therapies for the field of stem and cellular medicine, today announced second quarter 2022 financial results and provided a corporate update. “During our second quarter, we continued to advance multiple clinical programs for our anti-CD117 monoclonal antibody, JSP191, announcing the first patient enrolled in a trial in Fanconi Anemia, advancing...

Continue reading

Nocopi Q2 Revenue Improves Modestly to $514,300 on Stronger License and Royalty Income

Nocopi Q2 Revenue Improves Modestly to $514,300 on Stronger License and Royalty Income

KING OF PRUSSIA, Pa., Aug. 12, 2022 (GLOBE NEWSWIRE) — Nocopi Technologies, Inc. (OTC Pink: NNUP), a developer of specialty reactive inks used in entertainment, toy and educational products as well as in document and product authentication technologies to combat fraud, today announced results for its second quarter ended June 30, 2022 (Q2 ’22). Nocopi’s SEC filings are available here. Q2’22 ResultsQ2’22 revenue increased to $514,300 as compared to Q2’21 revenue of $513,900, principally reflecting an increase in license and royalty revenue offset by a decrease in specialty ink purchases by Asia-based printers. Demand for Nocopi’s specialty ink offerings continues to be impacted by global supply chain challenges, including significant increases in international shipping costs, congestion at Chinese ports, as well as pandemic-related...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.